PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

NEW YORK, May 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02114391/PharmaPoint-Neuropathic-Pain---5EU-Drug-Forecast-and-Market-Analysis-to-2022.html

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

The French market will also see the entry of several pipeline drugs with novel, first-in-class mechanisms of action, such as CNV-2197944 (PDN and PHN) and CNV-1014802 (TN), which will add patient share. As is the case in the global market, the overall NP market in Germany will show growth over the forecast period that will be driven predominantly by growth in the PDN segment of the market. Due to the delayed launch of Versatis in Italy, the dominant NP drug classes in the Italian NP market in terms of market share are slightly different compared with the US and the rest of the EU. Similar to Italy, the overall NP market in Spain will show growth over the forecast period that will be driven predominantly by the PDN and PHN segments. Surprisingly, in the UK, the order of the three leading NP products is very different compared with the US and the rest of the EU.

Scope

- Overview of Neuropathic Pain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Neuropathic Pain market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic Pain.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in 5EU.
1 Table of Contents
2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 17
3 Disease Overview 19
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 21
3.1.1 Painful Diabetic Neuropathy 23
3.1.2 Postherpetic Neuralgia 24
3.1.3 Trigeminal Neuralgia 24
3.2 Etiology and Pathophysiology 25
3.2.1 Etiology 26
3.2.2 Pathophysiology 27
4 Disease Management 35
4.1 Diagnosis and Treatment Overview 35
4.1.1 Diagnosis 35
4.1.2 Treatment Overview and Guidelines 42
4.2 France 52
4.2.1 Diagnosis and Referral 52
4.2.2 Drug Treatment 53
4.3 Germany 55
4.3.1 Diagnosis and Referral 55
4.3.2 Drug Treatment 56
4.4 Italy 58
4.4.1 Diagnosis and Referral 58
4.4.2 Drug Treatment 60
4.5 Spain 61
4.5.1 Diagnosis and Referral 61
4.5.2 Drug Treatment 63
4.6 UK 64
4.6.1 Diagnosis and Referral 64
4.6.2 Drug Treatment 66
5 Competitive Assessment 69
5.1 Overview 69
5.2 Tricyclic Antidepressants 74
5.2.1 Overview 74
5.2.2 Efficacy 75
5.2.3 Safety 76
5.3 Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants) 77
5.3.1 Overview 77
5.3.2 Efficacy 78
5.3.3 Safety 79
5.3.4 Lyrica 80
5.4 Sodium Channel-Blocking Anticonvulsants (TN) 84
5.4.1 Overview 84
5.4.2 Efficacy 85
5.4.3 Safety 85
5.5 Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants) 86
5.5.1 Overview 86
5.5.2 Efficacy 87
5.5.3 Safety 87
5.5.4 Cymbalta 88
5.6 Opioids 90
5.6.1 Overview 90
5.6.2 Efficacy 91
5.6.3 Safety 92
5.6.4 Nucynta ER/Palexia SR 92
5.7 Topical Therapies 95
5.7.1 Overview 95
5.7.2 Efficacy 96
5.7.3 Safety 96
5.7.4 Lidoderm/Versatis 97
5.7.5 Qutenza 99
6 Unmet Need and Opportunity 104
6.1 Overview 104
6.2 Physician Knowledge or Awareness 105
6.2.1 Unmet Need 105
6.2.2 Gap Analysis 106
6.2.3 Opportunity 107
6.3 Diagnostic Challenges 107
6.3.1 Unmet Need 107
6.3.2 Gap Analysis 108
6.3.3 Opportunity 108
6.4 Low Treatment Rate and Underdosing of Medications 108
6.4.1 Unmet Need 108
6.4.2 Gap Analysis 110
6.4.3 Opportunity 110
6.5 Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments 111
6.5.1 Unmet Need 111
6.5.2 Gap Analysis 112
6.5.3 Opportunity 112
6.6 Elderly Patient Population - Drug Tolerability 113
6.6.1 Unmet Need 113
6.6.2 Gap Analysis 113
6.6.3 Opportunity 114
6.7 Rational or Personalized Therapies 114
6.7.1 Unmet Need 114
6.7.2 Gap Analysis 115
6.7.3 Opportunity 115
7 Pipeline Assessment 117
7.1 Overview 117
7.2 Promising Drugs in Clinical Development 118
7.2.1 Eslicarbazepine Acetate 120
7.2.2 Topical Clonidine Gel 124
7.2.3 Cebranopadol 127
7.2.4 DS-5565 130
7.2.5 CNV-2197944 134
7.2.6 CNV-1014802 137
7.2.7 Eladur (bupivacaine patch) 140
8 Market Outlook 144
8.1 Drivers and Barriers - Global Issues 144
8.1.1 Driver: Aging Population in the 7MM 144
8.1.2 Driver: Increase in Prevalence and Diagnosis of Type 2 Diabetes Will Grow the PDN Market 144
8.1.3 Driver: Approval of New NP Drugs 145
8.1.4 Barrier: NP Market Dominated by Generics 145
8.1.5 Barrier: Challenges Selecting the Most Relevant Pathophysiological Targets for Drug Development 145
8.1.6 Barrier: Underserved Trigeminal Neuralgia Indication 146
8.1.7 Barrier: Competition from Interventional Therapies 146
8.2 France 147
8.2.1 Forecast 147
8.2.2 Key Events 157
8.2.3 Drivers and Barriers 157
8.3 Germany 159
8.3.1 Forecast 159
8.3.2 Key Events 169
8.3.3 Drivers and Barriers 169
8.4 Italy 172
8.4.1 Forecast 172
8.4.2 Key Events 182
8.4.3 Drivers and Barriers 182
8.5 Spain 184
8.5.1 Forecast 184
8.5.2 Key Events 194
8.5.3 Drivers and Barriers 194
8.6 United Kingdom 196
8.6.1 Forecast 196
8.6.2 Key Events 206
8.6.3 Drivers and Barriers 206
9 Appendix 209
9.1 Bibliography 209
9.2 Abbreviations 220
9.3 Methodology 225
9.4 Forecasting Methodology 225
9.4.1 Diagnosed PDN, PHN, and TN Patients 225
9.4.2 Percent Drug-Treated Patients 226
9.4.3 Drugs Included In Each Therapeutic Class 226
9.4.4 Launch and Patent Expiry Dates 226
9.4.5 General Pricing Assumptions 227
9.4.6 Individual Drug Assumptions 228
9.4.7 Generic Erosion 231
9.4.8 Pricing of Pipeline Agents 232
9.5 Physicians and Specialists Included in This Study 233
9.6 About the Authors 235
9.6.1 Author 235
9.6.2 Global Head of Healthcare 236
9.7 About GlobalData 237
9.8 Disclaimer 237

1.1 List of Tables

Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage 21
Table 2: Signs and Symptoms of NP 22
Table 3: Screening Tools for NP 36
Table 4: NP-Related Signs and Symptoms 38
Table 5: Treatment Guidelines for NP 43
Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy 49
Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012 51
Table 8: France - NP Diagnosis and Referral Metrics 53
Table 9: France - NP Treatment Metrics 54
Table 10: Germany - NP Diagnosis and Referral Metrics 56
Table 11: Germany - NP Treatment Metrics 58
Table 12: Italy - NP Diagnosis and Referral Metrics 59
Table 13: Italy - NP Treatment Metrics 61
Table 14: Spain - NP Diagnosis and Referral Metrics 62
Table 15: Spain - NP Treatment Metrics 64
Table 16: UK - NP Diagnosis and Referral Metrics 66
Table 17: UK - NP Treatment Metrics 68
Table 18: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013 71
Table 19: Select Products Used for NP Treatment, 2013 73
Table 20: Product Profile - Lyrica 81
Table 21: Lyrica SWOT Analysis, 2013 83
Table 22: Product Profile - Cymbalta 88
Table 23: Cymbalta SWOT Analysis, 2013 90
Table 24: Product Profile - Nucynta ER/Palexia SR 93
Table 25: Nucynta ER/Palexia SR SWOT Analysis, 2013 94
Table 26: Product Profile - Lidoderm/Versatis 98
Table 27: Lidoderm/Versatis SWOT Analysis, 2013 99
Table 28: Product Profile - Qutenza 101
Table 29: Qutenza SWOT Analysis, 2013 103
Table 30: Unmet Need and Opportunity in NP 105
Table 31: NP - Promising Drugs in Clinical Development 119
Table 32: Comparison of Drugs in Development for NP, 2014 119
Table 33: Product Profile - Eslicarbazepine Acetate 121
Table 34: Phase II: Efficacy of Eslicarbazepine Acetate in PHN 122
Table 35: Phase II: Efficacy of Eslicarbazepine Acetate in PDN 122
Table 36: Eslicarbazepine Acetate SWOT Analysis, 2013 124
Table 37: Product Profile - Topical Clonidine Gel 125
Table 38: Topical Clonidine Gel SWOT Analysis, 2013 127
Table 39: Product Profile - Cebranopadol 128
Table 40: Cebranopadol SWOT Analysis, 2013 130
Table 41: Product Profile - DS-5565 132
Table 42: DS-5565 SWOT Analysis, 2013 134
Table 43: Product Profile - CNV-2197944 135
Table 44: CNV-2197944 SWOT Analysis, 2013 137
Table 45: Product Profile - CNV1014802 138
Table 46: CNV-1014802 SWOT Analysis, 2013 140
Table 47: Product Profile - Eladur 141
Table 48: Eladur SWOT Analysis, 2013 143
Table 49: NP Market - Drivers and Barriers, 2012-2022 144
Table 50: Sales Forecasts ($) for NP in France, 2012-2022 149
Table 51: Sales Forecasts ($) for PDN in France, 2012-2022 151
Table 52: Sales Forecasts ($) for PHN in France, 2012-2022 153
Table 53: Sales Forecasts ($) for TN in France, 2012-2022 155
Table 54: Key Events Impacting Sales for NP in France, 2012-2022 157
Table 55: NP Market- Drivers and Barriers in France, 2012-2022 157
Table 56: Sales Forecasts ($) for NP in Germany, 2012-2022 161
Table 57: Sales Forecasts ($) for PDN in Germany, 2012-2022 163
Table 58: Sales Forecasts ($) for PHN in Germany, 2012-2022 165
Table 59: Sales Forecasts ($) for TN in Germany, 2012-2022 167
Table 60: Key Events Impacting Sales for NP in Germany, 2012-2022 169
Table 61: NP Market - Drivers and Barriers in Germany, 2012-2022 169
Table 62: Sales Forecasts ($) for NP in Italy, 2012-2022 174
Table 63: Sales Forecasts ($) for PDN in Italy, 2012-2022 176
Table 64: Sales Forecasts ($) for PHN in Italy, 2012-2022 178
Table 65: Sales Forecasts ($) for TN in Italy, 2012-2022 180
Table 66: Key Events Impacting Sales for NP in Italy, 2012-2022 182
Table 67: NP Market- Drivers and Barriers in Italy, 2012-2022 182
Table 68: Sales Forecasts ($) for NP in Spain, 2012-2022 186
Table 69: Sales Forecasts ($) for PDN in Spain, 2012-2022 188
Table 70: Sales Forecasts ($) for PHN in Spain, 2012-2022 190
Table 71: Sales Forecasts ($) for TN in Spain, 2012-2022 192
Table 72: Key Events Impacting Sales for NP in Spain, 2012-2022 194
Table 73: NP Market- Drivers and Barriers in Spain, 2012-2022 194
Table 74: Sales Forecasts ($) for NP in the UK, 2012-2022 198
Table 75: Sales Forecasts ($) for PDN in the UK, 2012-2022 200
Table 76: Sales Forecasts ($) for PHN in the UK, 2012-2022 202
Table 77: Sales Forecasts ($) for TN in the UK, 2012-2022 204
Table 78: Key Events Impacting Sales for NP in the UK, 2012-2022 206
Table 79: NP Market - Drivers and Barriers in the UK, 2012-2022 206
Table 80: Key Launch Dates 226
Table 81: Key Patent/Exclusivity Expiries 227

1.2 List of Figures

Figure 1: Nociceptive Versus Neuropathic Pain 20
Figure 2: Etiology and Pathophysiology of NP 25
Figure 3: Pain Pathway - Somatosensory System 28
Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System 32
Figure 5: Pathophysiological Targets of NP Drugs 33
Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP 39
Figure 7: General Treatment Algorithm for NP 48
Figure 8: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022 120
Figure 9: Sales for NP in France by Drug Class, 2012-2022 150
Figure 10: Sales for PDN in France by Drug Class, 2012-2022 152
Figure 11: Sales for PHN in France by Drug Class, 2012-2022 154
Figure 12: Sales for TN in France by Drug Class, 2012-2022 156
Figure 13: Sales for NP in Germany by Drug Class, 2012-2022 162
Figure 14: Sales for PDN in Germany by Drug Class, 2012-2022 164
Figure 15: Sales for PHN in Germany by Drug Class, 2012-2022 166
Figure 16: Sales for TN in Germany by Drug Class, 2012-2022 168
Figure 17: Sales for NP in Italy by Drug Class, 2012-2022 175
Figure 18: Sales for PDN in Italy by Drug Class, 2012-2022 177
Figure 19: Sales for PHN in Italy by Drug Class, 2012-2022 179
Figure 20: Sales for TN in Italy by Drug Class, 2012-2022 181
Figure 21: Sales for NP in Spain by Drug Class, 2012-2022 187
Figure 22: Sales for PDN in Spain by Drug Class, 2012-2022 189
Figure 23: Sales for PHN in Spain by Drug Class, 2012-2022 191
Figure 24: Sales for TN in Spain by Drug Class, 2012-2022 193
Figure 25: Sales for NP in the UK by Drug Class, 2012-2022 199
Figure 26: Sales for PDN in the UK by Drug Class, 2012-2022 201
Figure 27: Sales for PHN in the UK by Drug Class, 2012-2022 203
Figure 28: Sales for TN in the UK by Drug Class, 2012-2022 205


To order this report: PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02114391/PharmaPoint-Neuropathic-Pain---5EU-Drug-Forecast-and-Market-Analysis-to-2022.html



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.